AT515178A5 - Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie - Google Patents

Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie Download PDF

Info

Publication number
AT515178A5
AT515178A5 ATA9306/2013A AT93062013A AT515178A5 AT 515178 A5 AT515178 A5 AT 515178A5 AT 93062013 A AT93062013 A AT 93062013A AT 515178 A5 AT515178 A5 AT 515178A5
Authority
AT
Austria
Prior art keywords
curcumin
minimize
nanocurcumin
plga
liposomal
Prior art date
Application number
ATA9306/2013A
Other languages
English (en)
Other versions
AT515178A2 (de
Inventor
Amalendu Prakash Ranjan
Anindita Mukerjee
Jamboor K Vishwanatha
Lawrence Helson
Original Assignee
Univ North Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Texas filed Critical Univ North Texas
Publication of AT515178A2 publication Critical patent/AT515178A2/de
Publication of AT515178A5 publication Critical patent/AT515178A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung beinhaltet Zusammensetzungen und Verfahren zum Herstellen einer Nanopartikel-Zusammensetzung, welche einen polymeren Kern enthält, der mindestens ein Polymer und mindestens einen Wirkstoff und mindestens eine Schicht mindestens eines Lipids auf der Oberfläche des polymeren Kerns enthält; insbesondere betrifft die Erfindung die Verwendung von Curcumin in einer solchen Lipid-Polymer-Nanopartikel-Formulierung zur Minimierung der QT-Verlängerung in Verbindung mit Curcumin bei der Behandlung von Krebs.
ATA9306/2013A 2012-08-31 2013-08-31 Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie AT515178A5 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695827P 2012-08-31 2012-08-31
US14/016,056 US9138411B2 (en) 2012-08-31 2013-08-31 Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy

Publications (2)

Publication Number Publication Date
AT515178A2 AT515178A2 (de) 2015-06-15
AT515178A5 true AT515178A5 (de) 2015-07-15

Family

ID=50184475

Family Applications (1)

Application Number Title Priority Date Filing Date
ATA9306/2013A AT515178A5 (de) 2012-08-31 2013-08-31 Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie

Country Status (5)

Country Link
US (2) US9138411B2 (de)
AT (1) AT515178A5 (de)
CA (1) CA2882978A1 (de)
DE (1) DE112013004278T5 (de)
WO (1) WO2014036534A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393198B2 (en) 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US8753674B2 (en) 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10532045B2 (en) 2013-12-18 2020-01-14 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
AU2015269699B2 (en) 2014-06-03 2020-08-13 Avanti Polar Lipids, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies
RU2571270C1 (ru) * 2014-07-17 2015-12-20 Открытое Акционерное Общество "Фаберлик" Липосомальное наносредство на основе продуктов, полученных из корневищ куркумы
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
EP3142702B1 (de) 2015-04-17 2018-01-03 Veliddin Canfeza Sezgin Herstellung von curcumin- und piperinbeladenen, auf doppelschichtbiopolymer basierenden nanoabgabesystemen mittels elektrospray-/beschichtungsverfahren
AU2017257496B2 (en) * 2016-04-27 2020-05-07 Signpath Pharma, Inc. Prevention of drug-induced atrio-ventricular block
MX2019004222A (es) * 2016-10-19 2019-06-10 Signpath Pharma Inc Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias.
KR20240145085A (ko) 2017-10-19 2024-10-04 사인패스 파마 인코포레이티드 채널병증을 야기하는 약물에 대한 DMPC, DMPG, DMPC/DMPG, LysoPG 및 LysoPC의 보호 효과
US10912843B2 (en) * 2018-04-04 2021-02-09 National Cheng Kung University Endoplasmic reticulum-targeting nanovehicles and methods for use thereof
TWI737974B (zh) * 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
US20210315830A1 (en) 2018-08-31 2021-10-14 Council Of Scientific And Industrial Research A curcumin loaded stabilized polymeric nanoparticles with increased solubility and photo-stability and a green process for the synthesis thereof
CN109381447B (zh) * 2018-12-10 2021-01-26 上海交通大学医学院附属第九人民医院 一种载虾青素磷脂纳米粒及其制备方法与应用
KR102353979B1 (ko) * 2020-02-28 2022-01-20 가천대학교 산학협력단 전기분무로 제조된 고분자 리포좀 나노입자 제조방법
WO2021176264A1 (en) * 2020-03-02 2021-09-10 Yogesh Dound Liposomal compositions and process for preparation thereof
US20240180852A1 (en) * 2021-03-03 2024-06-06 Signpath Pharma, Inc. Treatment for malignant pleural effusion in humans
CN116173233A (zh) * 2023-01-30 2023-05-30 北京大学第一医院 Pd-1靶向负载姜黄素的纳米制剂、制备及在肾脏疾病的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048598A1 (en) * 1997-06-13 2002-04-25 Navid Malik Internally supported lipid vesicle systems
WO2007103435A2 (en) * 2006-03-06 2007-09-13 The Regents Of The University Of California Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
US20080138400A1 (en) * 2004-03-05 2008-06-12 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US20080253961A1 (en) * 2007-04-13 2008-10-16 University Of North Texas Health Science Center At Fort Worth Formulation of Active Agent Loaded Activated PLGA Nanoparticles for Targeted Cancer Nano-Therapeutics
US20110117186A1 (en) * 2009-11-19 2011-05-19 Lawrence Helson Intravenous infusion of curcumin and a calcium channel blocker

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US4812312A (en) 1987-03-03 1989-03-14 Board Of Regents Of The University Of Texas System Liposome-incorporated nystatin
US5679864A (en) 1995-11-03 1997-10-21 Gene Print Inc. Process for the synthesis of curcumin-related compounds
JP3272256B2 (ja) 1997-01-17 2002-04-08 丸善製薬株式会社 クルクミノイドの安定化法および安定化クルクミノイド組成物
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US20010051184A1 (en) 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
WO2002019966A2 (en) 2000-09-06 2002-03-14 Johns Hopkins University Cardiac arrhythmia treatment methods
US7060733B2 (en) 2002-08-15 2006-06-13 The Regents Of The University Of California Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
EG23547A (en) 2002-11-25 2006-05-10 Mallah Ahmed Ibrahim Mohame El Preparation of a topical pharmaceutical preparation of curcumin alone or a combination of circumin plus capsaicin as an effective remedy for treatmentof peripheral neuropathies
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
WO2004080396A2 (en) 2003-03-07 2004-09-23 The University Of Texas Md Anderson Cancer Center Liposomal curcumin for treatment of cancer
WO2005018635A2 (en) 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
WO2005020958A2 (en) 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
US7067159B2 (en) 2003-12-05 2006-06-27 New Chapter, Inc. Methods for treating prostate cancer with herbal compositions
US20050266067A1 (en) 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
US20080103213A1 (en) 2004-03-05 2008-05-01 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of neurofibromatosis
US20050233970A1 (en) 2004-03-23 2005-10-20 Praecis Pharmaceuticals, Inc. Methods for treating long QT syndrome
EP3153159A1 (de) 2004-07-09 2017-04-12 Robert Sabin Zusammensetzungen mit einer kupferverbindung zur behandlung von erkrankungen bei säugetieren
US20090285878A1 (en) 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
US20090143433A1 (en) 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
ITMI20042353A1 (it) 2004-12-10 2005-03-10 Uni Degli Studi Di Modena E Re Peptidi per la veicolazione di farmaci
US8202839B1 (en) 2005-01-04 2012-06-19 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
PT1890546T (pt) 2005-05-30 2019-01-23 Antony Benny Método para melhorar a biodisponibilidade da curcumina
KR20080021707A (ko) 2005-06-30 2008-03-07 솔루티아 인코포레이티드 임팩트 저항, 직접 접촉 플라즈마 디스플레이 패널 필터
EP2037762A4 (de) 2006-06-05 2009-07-08 Darrick S H L Kim Verfahren zur herstellung von reinem curcumin
US7507864B2 (en) 2006-08-01 2009-03-24 Salisbury University Method for the synthesis of curcumin analogues
US20080075671A1 (en) 2006-09-22 2008-03-27 Di Mauro Thomas M Intranasally administering curcumin to the brain to treat alzheimer's disease
US7593764B2 (en) 2006-10-03 2009-09-22 General Electric Company System and method of serial comparison for detection of long QT syndrome (LQTS)
US8313777B2 (en) 2006-10-05 2012-11-20 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
AU2007306936B2 (en) 2006-10-12 2014-02-06 The University Of Queensland Compositions and methods for modulating immune responses
WO2008045534A2 (en) 2006-10-12 2008-04-17 Research Foundation Of The City University Of New York Novel curcumin and tetrahydrocurcumin derivatives
EP2152252A4 (de) 2006-11-13 2010-06-02 Univ Columbia Selektive proteasom-hemmer zur behandlung von diabetes
US7871609B2 (en) 2007-03-02 2011-01-18 Sam Ziff Supplements for pain management
US20080255464A1 (en) 2007-04-10 2008-10-16 Vincent G Michael System and method for diagnosing and treating long qt syndrome
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
US20090246770A1 (en) 2007-11-01 2009-10-01 Andrew Levy Glycemic control for reduction of cardiovascular disease risk in diabetic patients expressing haptoglobin 2-2
US8062663B2 (en) 2008-05-23 2011-11-22 National Health Research Instittues Methods and compostions for enhancing transdermal drug delivery
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010009186A1 (en) 2008-07-15 2010-01-21 The Board Of Trustees Of The University Of Illinois Liposome formulation having hydrophilic and hydrophobic pharmaceutical compounds co-encapsulated therein
US20100179103A1 (en) 2008-07-21 2010-07-15 Ketan Desai Curcumin cyclodextrin combination for preventing or treating various diseases
US20120003177A1 (en) 2008-09-17 2012-01-05 Youqing Shen Curcumin-containing polymers and water-soluble curcumin derivatives as prodrugs of prodrug carriers
US20100093873A1 (en) 2008-10-02 2010-04-15 Goldfischer Sidney L Methods of improving therapy of perfluorocarbons (PFC)
WO2010057332A1 (en) 2008-11-19 2010-05-27 Telefonaktiebolaget L M Ericsson (Publ) Provisioning method and system
WO2010083337A2 (en) 2009-01-15 2010-07-22 The Regents Of The University Of Califorinia Composite nanostructures and methods for making and using them
US7723515B1 (en) 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
US20100239552A1 (en) 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination Therapies for Treating Metabolic Disorders
CN102470098A (zh) 2009-07-01 2012-05-23 皇家飞利浦电子股份有限公司 用于mpi引导的药物递送的刺激-响应性载体
US9393198B2 (en) 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
US20120058208A1 (en) 2010-09-04 2012-03-08 Synthite Industries Ltd. Synergistic Composition for Enhancing Bioavailability of Curcumin
WO2012054718A2 (en) 2010-10-22 2012-04-26 The General Hospital Corporation Treating long qt syndrome
EP2685963A4 (de) 2011-03-16 2014-11-19 Signpath Pharma Inc Curcumin-kombination mit wirkstoffen gegen diabetes vom typ 2 und zur behandlung von krankheits-folgeleiden, wirkstoffvermittelten nebenwirkungen und verbesserter glykämiesteuerung
US8753674B2 (en) 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
HK1208907A1 (en) 2012-06-14 2016-03-18 Signpath Pharma Inc. Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048598A1 (en) * 1997-06-13 2002-04-25 Navid Malik Internally supported lipid vesicle systems
US20080138400A1 (en) * 2004-03-05 2008-06-12 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
WO2007103435A2 (en) * 2006-03-06 2007-09-13 The Regents Of The University Of California Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
US20080253961A1 (en) * 2007-04-13 2008-10-16 University Of North Texas Health Science Center At Fort Worth Formulation of Active Agent Loaded Activated PLGA Nanoparticles for Targeted Cancer Nano-Therapeutics
US20110117186A1 (en) * 2009-11-19 2011-05-19 Lawrence Helson Intravenous infusion of curcumin and a calcium channel blocker

Also Published As

Publication number Publication date
AT515178A2 (de) 2015-06-15
US20150258026A1 (en) 2015-09-17
CA2882978A1 (en) 2014-03-06
DE112013004278T5 (de) 2015-05-21
US20140065061A1 (en) 2014-03-06
US9138411B2 (en) 2015-09-22
WO2014036534A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
AT515178A5 (de) Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie
BR112014029206A2 (pt) pós hemostáticos de celulose regenerada oxidada e métodos para fabricação dos mesmos
JP2016504362A5 (de)
EP3811939A4 (de) Pharmazeutische kombination, zusammensetzung und formulierung mit einem glucokinase-aktivator und einem alpha-glucosidase-inhibitor sowie verfahren zu ihrer herstellung und verwendungen davon
AR128748A2 (es) Compuestos sustituidos de aminopurina, sus composiciones y métodos de tratamiento con ellos
NZ630912A (en) Nanoparticle compositions of albumin and paclitaxel
WO2018115097A9 (en) Ophthalmic composition for treatment of dry eye disease
BR112017016093A2 (pt) composição sólida, curativo de ferida, e, método de fabricação de uma composição
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
WO2018115231A3 (en) Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
MX2017004579A (es) Estructuras fibrosas solubles y metodos para fabricarlas.
EP3424907A3 (de) Verbindungen und organische elektronische vorrichtungen
PE20141792A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
AR071239A1 (es) Microesferas que tienen una estructura de nucleo / recubrimiento que comprenden aripiprazol y uso
BR112017016100A2 (pt) composição, curativo de ferida, e, método de fabricação de uma composição.
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112017016072A2 (pt) ?composição, curativo de ferida, e, método de fabricação de uma composição?
WO2016137235A3 (ko) 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물
BR112016013684A2 (pt) Solução aquosa ou hidrocoloide, método para aumentar a viscosidade de uma composição e método para o tratamento de um material
MY190392A (en) A delayed release drug formulation
WO2014004993A3 (en) Methods of reducing ldl-p
AR091220A1 (es) Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
WO2015152693A3 (ko) 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
MX2018005971A (es) Composicion farmaceutica novedosa que comprende particulas que comprenden un complejo de un polirribonucleotido de hebra doble y una polialquilenimina.

Legal Events

Date Code Title Description
REJ Rejection

Effective date: 20180215